Log in
LON:DPH

Dechra Pharmaceuticals PLC (DPH.L) Share Forecast, Price & News

GBX 3,546
-20.00 (-0.56 %)
(As of 10/28/2020 12:55 PM ET)
Add
Compare
Today's Range
3,510
Now: GBX 3,546▼
3,578
50-Day Range
3,156
MA: GBX 3,320.08▼
3,566
52-Week Range
2,030
Now: GBX 3,546▼
3,608.91
Volume33,851 shs
Average Volume262,321 shs
Market Capitalization£3.83 billion
P/E Ratio108.11
Dividend Yield0.98%
BetaN/A
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More
Dechra Pharmaceuticals PLC (DPH.L) logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.71 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolLON:DPH
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.dechra.com
Phone+44-1606-814730
Employees1,889

Debt

Debt-to-Equity Ratio55.69
Current Ratio3.27
Quick Ratio2.37

Price-To-Earnings

Trailing P/E Ratio108.11
Forward P/E Ratio0.36
P/E GrowthN/A

Sales & Book Value

Annual Sales£515.10 million
Price / Sales7.44
Cash FlowGBX 209.79 per share
Price / Cash Flow16.90
Book ValueGBX 590.20 per share
Price / Book6.01

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares108,079,000
Market Cap£3.83 billion
Next Earnings DateN/A
OptionableNot Optionable
GBX 3,546
-20.00 (-0.56 %)
(As of 10/28/2020 12:55 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dechra Pharmaceuticals PLC (DPH.L) (LON:DPH) Frequently Asked Questions

How has Dechra Pharmaceuticals PLC (DPH.L)'s stock price been impacted by Coronavirus (COVID-19)?

Dechra Pharmaceuticals PLC (DPH.L)'s stock was trading at GBX 2,472 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DPH shares have increased by 43.4% and is now trading at GBX 3,546.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Dechra Pharmaceuticals PLC (DPH.L)?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals PLC (DPH.L) in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Dechra Pharmaceuticals PLC (DPH.L).

How often does Dechra Pharmaceuticals PLC (DPH.L) pay dividends? What is the dividend yield for Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L) declared a dividend on Monday, September 7th. Investors of record on Thursday, November 5th will be given a dividend of GBX 24 per share on Friday, November 27th. This represents a yield of 0.73%. The ex-dividend date of this dividend is Thursday, November 5th. This is a boost from Dechra Pharmaceuticals PLC (DPH.L)'s previous dividend of GBX 10.29. The official announcement can be seen at this link.
View Dechra Pharmaceuticals PLC (DPH.L)'s dividend history.

What price target have analysts set for DPH?

4 Wall Street analysts have issued 1 year target prices for Dechra Pharmaceuticals PLC (DPH.L)'s stock. Their forecasts range from GBX 2,510 to GBX 3,515. On average, they expect Dechra Pharmaceuticals PLC (DPH.L)'s stock price to reach GBX 3,077.50 in the next twelve months. This suggests that the stock has a possible downside of 13.2%.
View analysts' price targets for Dechra Pharmaceuticals PLC (DPH.L).

Who are some of Dechra Pharmaceuticals PLC (DPH.L)'s key competitors?

Some companies that are related to Dechra Pharmaceuticals PLC (DPH.L) include Hutchison China MediTech Limited (HCM.L) (HCM), Vectura Group (VEC), Beximco Pharmaceuticals Limited (BXP.L) (BXP), ECO Animal Health Group plc (EAH.L) (EAH), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), NanoViricides (NNVC), Futura Medical plc (FUM.L) (FUM), Sareum Holdings plc (SAR.L) (SAR), Cathay International (CTI), Avivagen Inc. (VIV.V) (VIV), China Pharma (CPHI), N4 Pharma Plc (N4P.L) (N4P), Antisense Therapeutics Limited (ANP.AX) (ANP) and Bayer (BAYN).
View all competitors.

What other stocks do shareholders of Dechra Pharmaceuticals PLC (DPH.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals PLC (DPH.L) investors own include (TTR.L) (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion plc (JD.L) (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group plc (DRX.L) (DRX), RPC Group (RPC), Robert Walters (RWA), SkyePharma (SKP) and Barratt Developments plc (BDEV.L) (BDEV).

Who are Dechra Pharmaceuticals PLC (DPH.L)'s key executives?

Dechra Pharmaceuticals PLC (DPH.L)'s management team includes the following people:
  • Mr. Ian D. Page, CEO, MD & Exec. Director (Age 59, Pay $793k)
  • Mr. Paul Nicholas Sandland MAAT, FCCA, CFO & Exec. Director (Age 41, Pay $375.6k)
  • Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 57, Pay $466k)
  • Dr. Susan Longhofer, Chief Scientific Officer (Age 62)
  • Ms. Katy Clough, Group HR Director
  • Mr. Mike Eldred, Pres of North America (Age 50)
  • Ms. Melanie Hall, Company Sec.

What is Dechra Pharmaceuticals PLC (DPH.L)'s stock symbol?

Dechra Pharmaceuticals PLC (DPH.L) trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals PLC (DPH.L)?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Dechra Pharmaceuticals PLC (DPH.L)'s stock price today?

One share of DPH stock can currently be purchased for approximately GBX 3,546.

How big of a company is Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L) has a market capitalization of £3.83 billion and generates £515.10 million in revenue each year. Dechra Pharmaceuticals PLC (DPH.L) employs 1,889 workers across the globe.

What is Dechra Pharmaceuticals PLC (DPH.L)'s official website?

The official website for Dechra Pharmaceuticals PLC (DPH.L) is www.dechra.com.

How can I contact Dechra Pharmaceuticals PLC (DPH.L)?

Dechra Pharmaceuticals PLC (DPH.L)'s mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.

This page was last updated on 10/28/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.